Heart disease patients switch drugs in hope for better control

NCT ID NCT07298044

Not yet recruiting Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

Summary

This study is for adults with a heart disease where a protein forms harmful clumps, making it hard for the heart to pump. Researchers want to see if switching patients from their current drug (tafamidis) to a newer one (acoramidis) increases the level of the good protein in their blood more effectively. About 50 participants will take acoramidis for 6 months while doctors check their blood, heart, and kidney function.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Klinik Favoriten - 5.Medizinische Abteilung-Kardiologie

    Vienna, Vienna, 1100, Austria

  • Klinik Ottakring - 3. Medizinische Abteilung mit Kardiologie, internistischer Intensivmedizin und Ambulanz

    Vienna, Vienna, 3500, Austria

  • Medizinische Universität Graz- Klinische Abteilung für Kardiologie

    Vienna, Styria, 1030, Austria

  • Medizinische Universität Wien- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie

    Vienna, Vienna, 1090, Austria

  • Universitätsklinikum St. Pölten - Lilienfeld - Klinische Abteilung für Innere Medizin 3

    Sankt Pölten, Lower Austria, 1210, Austria

Conditions

Explore the condition pages connected to this study.